Introduction

Fenitab 200 mg (Sorafenib) Tablet is an oral multikinase inhibitor designed to treat unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). Manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified leader in oncology therapeutics, and supplied globally by Onco Solution, this targeted therapy disrupts tumor growth and angiogenesis by inhibiting critical kinases involved in cancer progression. Fenitab 200 mg (Sorafenib) Tablet offers a balance of efficacy and manageable toxicity, making it a cornerstone treatment for advanced liver and kidney cancers.

Key Benefits & Mechanism of Action

Fenitab 200 mg (Sorafenib) Tablet targets multiple kinases to combat cancer progression through two primary mechanisms:

1. Tumor Cell Proliferation Inhibition:
   • Blocks intracellular kinases CRAF, BRAF (including mutant BRAF), disrupting the RAF/MEK/ERK signaling pathway essential for cancer cell division.
2. Angiogenesis Suppression:
   • Inhibits cell surface kinases VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, reducing blood supply to tumors by preventing new blood vessel formation.
3. Apoptosis Induction:
   • Promotes cancer cell death by interfering with survival signals mediated by KIT, FLT-3, and RET kinases.

Indications

Fenitab 200 mg (Sorafenib) Tablet is approved for:

• Hepatocellular Carcinoma (HCC): First-line treatment for patients with unresectable liver cancer.
• Renal Cell Carcinoma (RCC): Therapy for advanced kidney cancer patients who may not benefit from immunotherapy.

Dosage & Administration

The recommended dose is 400 mg (two 200 mg tablets) twice daily, taken on an empty stomach (1 hour before or 2 hours after meals). Treatment continues until disease progression or intolerable toxicity.

Dose Adjustments

• Grade 2 Hand-Foot Skin Reaction (HFSR): Interrupt treatment if no improvement within 7 days; resume at 400 mg once daily.
• Grade 3 HFSR: Interrupt until toxicity resolves to Grade 0-1; restart at 400 mg every other day.
• Grade 4 Toxicity: Discontinue permanently.

Missed Dose
Skip the missed dose and resume the next dose at the scheduled time. Do not double the dose.

Pharmacology

Fenitab 200 mg (Sorafenib) Tablet’s dual action targets both tumor cells and their microenvironment:

• Antiproliferative Effects: Suppresses RAF/MEK/ERK signaling to slow tumor growth.
• Antiangiogenic Activity: Reduces VEGF-driven blood vessel formation, starving tumors of nutrients.

Contraindications

• Hypersensitivity to sorafenib or any tablet component.
• Squamous Cell Lung Cancer: Contraindicated with carboplatin/paclitaxel due to increased mortality risk.

Drug Interactions

Fenitab 200 mg (Sorafenib) Tablet interacts with several therapies, requiring careful monitoring:

• Docetaxel: Increases AUC by 36–80%; monitor for myelosuppression.
• Doxorubicin: Elevates exposure by 21%; adjust doses cautiously.
• CYP3A4 Inducers (e.g., Rifampicin): Reduce sorafenib efficacy by 37%; avoid St. John’s wort.
• UGT1A1 Substrates (e.g., Irinotecan): May increase toxicity due to elevated plasma levels.

Side Effects

Common Reactions

• Dermatologic: Hand-foot skin reaction (30–40%), rash (25%), alopecia (15%).
• Gastrointestinal: Diarrhea (40%), nausea (20%), vomiting (10%).
• Cardiovascular: Hypertension (10–17%), fatigue (35%).

Serious Adverse Events

• Cardiac Ischemia/Infarction: Monitor for chest pain; discontinue if confirmed.
• Hemorrhage: Risk of gastrointestinal or cerebral bleeding; discontinue if severe.
• Gastrointestinal Perforation: Immediate discontinuation required.

Precautions & Warnings

• Hypertension: Check blood pressure weekly; initiate antihypertensives if needed.
• Wound Healing: Suspend therapy pre- and post-major surgery until wound heals.
• Pregnancy/Lactation: Contraindicated due to fetal harm risk; avoid breastfeeding.

Use in Special Populations

• Hepatic Impairment: Safe in Child-Pugh A/B HCC patients; avoid in Child-Pugh C.
• Renal Impairment: No dose adjustment needed.
• Geriatric Patients: Safety profile comparable to younger adults.

Overdose Management

No specific antidote exists. The maximum studied dose (800 mg twice daily) caused severe diarrhea and skin toxicity. Provide symptomatic support and discontinue treatment.

Storage & Handling

Store below 30°C in the original container with desiccant. Do not transfer to other packaging.

Manufacturer Credibility

Eskayef Pharmaceuticals Ltd., a flagship of Bangladesh’s Transcom Group, has delivered affordable, high-quality oncology therapies since 1990. Their WHO-GMP-certified facilities ensure Fenitab 200 mg (Sorafenib) Tablet meets global standards. Learn more at www.skfbd.com.

Supplier Profile: Onco Solution

Onco Solution bridges global gaps in cancer care by supplying Fenitab 200 mg (Sorafenib) Tablet to 50+ countries. Services include:

• Bulk Procurement: Competitive pricing for hospitals and clinics.
• Clinical Resources: Access to dosing guidelines via www.oncosolution.com.
• Global Logistics: Reliable delivery to underserved regions.

Conclusion

Fenitab 200 mg (Sorafenib) Tablet is a vital therapy for advanced HCC and RCC, offering dual inhibition of tumor growth and angiogenesis. Trust Eskayef Pharmaceuticals Ltd. for quality and Onco Solution for global accessibility. For orders or clinical guidance, contact Onco Solution today.